{"id":14477,"date":"2012-01-20T09:30:00","date_gmt":"2012-01-20T08:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/2011-acquisizioni-per-224-mld-dollari\/"},"modified":"2012-01-20T09:30:00","modified_gmt":"2012-01-20T08:30:00","slug":"2011-acquisizioni-per-224-mld-dollari","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/2011-acquisizioni-per-224-mld-dollari\/","title":{"rendered":"2011, $224 billion in acquisitions"},"content":{"rendered":"<p style=\"line-height: normal; margin: 0cm 0cm 0pt; text-autospace: ; mso-layout-grid-align: none\" class=\"MsoNormal\"><span style=\"font-family: BookAntiqua; color: #212120; mso-bidi-font-family: BookAntiqua\"><font size=\"3\"><font face=\"Calibri\">The value of pharmaceutical mergers and acquisitions in 2011 rose to $224 billion, the highest since 2007 according to new research from international law firm Freshfields Bruckhaus Deringer. This is an increase of 18% since 2010, although lower than the record of 2006, when it reached 303 billion globally. <\/p>\n<p><\/font><\/font><\/span><\/p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0pt; text-autospace: ; mso-layout-grid-align: none\" class=\"MsoNormal\"><span style=\"font-family: BookAntiqua; color: #212120; mso-bidi-font-family: BookAntiqua\"><font size=\"3\"><font face=\"Calibri\">35% of bestselling drug patents is set to expire in the US in the next two years, and half are already without commercial protection. That&#039;s why industries aim to grab small companies, in many cases owning promising projects or located in growing markets. <\/p>\n<p><\/font><\/font><\/span><\/p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0pt; text-autospace: ; mso-layout-grid-align: none\" class=\"MsoNormal\"><span style=\"font-family: BookAntiqua; color: #212120; mso-bidi-font-family: BookAntiqua\"><font size=\"3\"><font face=\"Calibri\">In fact, the sector continues to focus on emerging countries: the value of transactions involving Brazilian, Indian, Chinese and Russian pharmaceuticals (Bric) in 2011 exceeds the total recorded in the last five years: it reached 6.4 billion dollars, 198% more than in 2006. <\/p>\n<p><\/font><\/font><\/span><\/p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0pt; text-autospace: ; mso-layout-grid-align: none\" class=\"MsoNormal\"><span style=\"font-family: BookAntiqua; color: #212120; mso-bidi-font-family: BookAntiqua\"><font size=\"3\"><font face=\"Calibri\">Mergers and acquisitions involving the BRIC economies represent 3% of the global total in the sector, compared to 0.8% in 2006 and 0.2% in 2000. &quot;The &#039;pharmerging&#039; market - comments Julian Long, head of the Health sector of the study - is the most obvious investment choice for Big Pharma&quot;.<\/p>\n<p><\/font><\/font><\/span><\/p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0pt; text-autospace: ; mso-layout-grid-align: none\" class=\"MsoNormal\"><em><span style=\"font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; color: #212120; font-size: 9.5pt; mso-bidi-font-weight: bold\">(BDC \u2013 January 20, 2012 \u2013 PharmaKronos)<\/span><\/em><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #f38e2c; font-size: 13pt; mso-bidi-font-weight: bold\"><\/p>\n<p><\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Il valore delle fusioni e acquisizioni nel settore farmaceutico nel 2011 &egrave; salito a 224 miliardi di dollari, il pi&ugrave; alto mai registrato dal 2007 secondo una nuova ricerca dello studio legale internazionale Freshfields Bruckhaus Deringer. Si tratta di una cifra in crescita del 18% rispetto al 2010, sebbene pi&ugrave; bassa del record del 2006, &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14477","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14477"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14477\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}